Since recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors are increasingly being considered as a first-line oral treatment for T2D, especially in patients with (an increased risk of) cardiovascular disease [50]. Here, SLC5A2 is linked to cardiovascular disorder.